Peterson Wealth Services Has $3.14 Million Position in Zoetis Inc. (NYSE:ZTS)

Peterson Wealth Services lifted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 13.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,093 shares of the company's stock after buying an additional 2,302 shares during the period. Peterson Wealth Services' holdings in Zoetis were worth $3,144,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Norges Bank acquired a new position in shares of Zoetis in the fourth quarter valued at approximately $824,321,000. Wellington Management Group LLP grew its holdings in shares of Zoetis by 78.5% in the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. Sarasin & Partners LLP acquired a new position in shares of Zoetis in the first quarter valued at approximately $339,111,000. GAMMA Investing LLC grew its holdings in shares of Zoetis by 14,731.3% in the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after purchasing an additional 1,747,423 shares in the last quarter. Finally, Capital Research Global Investors acquired a new position in shares of Zoetis in the fourth quarter valued at approximately $178,688,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS traded down $1.29 on Monday, reaching $147.31. The company had a trading volume of 2,996,578 shares, compared to its average volume of 2,624,290. The company has a fifty day moving average of $160.77 and a 200-day moving average of $161.42. The company has a market capitalization of $65.59 billion, a P/E ratio of 24.68, a PEG ratio of 2.46 and a beta of 0.91. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter last year, the firm posted $1.38 EPS. The business's revenue for the quarter was up 1.4% on a year-over-year basis. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.36%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is 35.91%.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

ZTS has been the subject of a number of research analyst reports. Piper Sandler increased their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $180.00 to $155.00 in a report on Thursday. Finally, Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $204.63.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.